Health Canada
- Status: approved
Fondaparinux background and low dose heparin (Fondaparinux background and low dose heparin) regulatory status in Canada.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. Health Canada has authorised it.
GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.